ZA974223B - Biphenylsulfonamide matrix metalloproteinase inhibitors. - Google Patents

Biphenylsulfonamide matrix metalloproteinase inhibitors.

Info

Publication number
ZA974223B
ZA974223B ZA9704223A ZA974223A ZA974223B ZA 974223 B ZA974223 B ZA 974223B ZA 9704223 A ZA9704223 A ZA 9704223A ZA 974223 A ZA974223 A ZA 974223A ZA 974223 B ZA974223 B ZA 974223B
Authority
ZA
South Africa
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
alkyl
biphenylsulfonamide
biphenylsulfonamide matrix
Prior art date
Application number
ZA9704223A
Other languages
English (en)
Inventor
Patrick Michael O'brien
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA974223B publication Critical patent/ZA974223B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
ZA9704223A 1996-05-17 1997-05-15 Biphenylsulfonamide matrix metalloproteinase inhibitors. ZA974223B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17

Publications (1)

Publication Number Publication Date
ZA974223B true ZA974223B (en) 1997-12-10

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9704223A ZA974223B (en) 1996-05-17 1997-05-15 Biphenylsulfonamide matrix metalloproteinase inhibitors.

Country Status (23)

Country Link
EP (1) EP0901466B1 (zh)
JP (1) JP2000511175A (zh)
KR (1) KR20000011095A (zh)
CN (1) CN1077885C (zh)
AT (1) ATE207891T1 (zh)
BG (1) BG63940B1 (zh)
BR (1) BR9710841A (zh)
CA (1) CA2253342A1 (zh)
CZ (1) CZ294063B6 (zh)
DE (1) DE69707865T2 (zh)
DK (1) DK0901466T3 (zh)
EA (1) EA001561B1 (zh)
EE (1) EE03965B1 (zh)
ES (1) ES2167733T3 (zh)
HK (1) HK1019585A1 (zh)
IL (1) IL126832A0 (zh)
NO (1) NO312510B1 (zh)
NZ (1) NZ332711A (zh)
PL (1) PL186416B1 (zh)
PT (1) PT901466E (zh)
SK (1) SK282863B6 (zh)
WO (1) WO1997044315A1 (zh)
ZA (1) ZA974223B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
ES2212142T3 (es) 1996-12-17 2004-07-16 Warner-Lambert Company Llc Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
WO1999004780A1 (fr) 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie
KR20010033473A (ko) * 1997-12-23 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃｅ 저해제-ｍｍｐ 저해제의 병용 제제
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
SK11692000A3 (sk) 1998-02-04 2001-02-12 Novartis Ag Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
KR20010041916A (ko) * 1998-03-17 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
DK1097159T3 (da) 1998-07-16 2003-03-10 Aventis Pharma Gmbh Phosphin- og phosphonsyrederivater som lægemidler
JP2002521328A (ja) * 1998-07-21 2002-07-16 ワーナー−ランバート・カンパニー アテローム性動脈硬化症病変の治療のためのａｃａｔ阻害剤およびｍｍｐ阻害剤の併用投与
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
PL351374A1 (en) * 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
KR100733752B1 (ko) 1999-11-26 2007-06-29 시오노기세이야쿠가부시키가이샤 Ｎｐｙｙ５ 길항제
EP1331224A4 (en) * 2000-09-29 2004-03-17 Shionogi & Co THIAZOLE AND OXAZOLE DERIVATIVES
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) * 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
AU2003304638A1 (en) 2003-12-04 2005-07-14 Wyeth Biaryl sulfonamides and methods for using same
JP2007530546A (ja) * 2004-03-22 2007-11-01 サザン リサーチ インスティチュート マトリックスメタロプロテイナーゼの非ペプチドインヒビター
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
IL126832A0 (en) 1999-08-17
JP2000511175A (ja) 2000-08-29
ES2167733T3 (es) 2002-05-16
DK0901466T3 (da) 2002-02-18
DE69707865D1 (de) 2001-12-06
CZ294063B6 (cs) 2004-09-15
NO312510B1 (no) 2002-05-21
KR20000011095A (ko) 2000-02-25
AU713286B2 (en) 1999-11-25
CN1077885C (zh) 2002-01-16
NO985326L (no) 1999-01-14
BG102918A (en) 1999-09-30
EA199800988A1 (ru) 1999-04-29
EP0901466B1 (en) 2001-10-31
CZ366898A3 (cs) 1999-02-17
CA2253342A1 (en) 1997-11-27
CN1219166A (zh) 1999-06-09
NZ332711A (en) 2000-06-23
DE69707865T2 (de) 2002-05-02
EE03965B1 (et) 2003-02-17
NO985326D0 (no) 1998-11-16
BG63940B1 (bg) 2003-07-31
PL329929A1 (en) 1999-04-26
HK1019585A1 (en) 2000-02-18
EA001561B1 (ru) 2001-04-23
SK157798A3 (en) 1999-04-13
EE9800397A (et) 1999-06-15
PT901466E (pt) 2002-04-29
WO1997044315A1 (en) 1997-11-27
PL186416B1 (pl) 2004-01-30
BR9710841A (pt) 1999-08-17
AU2680397A (en) 1997-12-09
SK282863B6 (sk) 2002-12-03
EP0901466A1 (en) 1999-03-17
ATE207891T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
IL126832A0 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
AU6894800A (en) Caspase inhibitors and uses thereof
GB9801690D0 (en) Therapeutic agents
WO2003024448A3 (en) Inhibitors of histone deacetylase
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
MX9606744A (es) Acidos hidroxamicos sustituidos por sulfonamido arilico como inhibidores de metaloproteinasa de matriz.
AU2001248701A1 (en) Inhibitors of histone deacetylase
PL312196A1 (en) Heterocyclic phenyl compounds as inhibitors of cyclooxygenase-2
AU2483000A (en) Treatment of asthma with mek inhibitors
PL332509A1 (en) Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
PL343495A1 (en) Heterocyclically substituted amides used as calpain inhibitors
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
AU1314300A (en) Methods and compositions for inhibiting polymerization of ethylenically unsaturated hydrocarbons
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
AU9066498A (en) Substituted 6-alkylphenanthridines
AU3729397A (en) Butyric acid matrix metalloproteinase inhibitors
PL317349A1 (en) Organic compounds
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.